Growing evidence has brought stem cell therapy to the front of MS research. However, it is not yet included in formal guidelines.
In an observational study, researchers explored the effectiveness and safety of autologous hematopoietic stem cell transplantation (aHSCT) when provided as part of routine health care.
The analysis included 174 relapsing-remitting MS (RRMS) patients treated with aHSCT in Sweden.
Results
Results indicated that most of these patients had no evidence of disease activity for 5-10 years post-treatment with acceptable side effects.
The researchers concluded that this treatment should be considered a standard of care for people with highly active RRMS.
For more info:
https://jnnp.bmj.com/content/early/2023/08/14/jnnp-2023-331864
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment.
